Anbozhi Lian

AmboLink is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company leverages its proprietary site-specific conjugation platform to create highly stable and homogeneous ADC candidates, aiming to overcome the limitations of traditional random conjugation methods. AmboLink's lead program, AL-001, is a HER2-targeted ADC currently in Phase 1 clinical trials for the treatment of solid tumors. The company's pipeline also includes candidates targeting Trop2 and Claudin-18.2, utilizing optimized linkers and potent payloads to enhance therapeutic efficacy. By integrating advanced enzymatic conjugation technologies, AmboLink seeks to improve the therapeutic index and clinical outcomes for cancer patients globally.